

# World Journal of *Hepatology*

*World J Hepatol* 2022 May 27; 14(5): 866-1052



**REVIEW**

- 866 Role of hepatitis B virus in development of hepatocellular carcinoma: Focus on covalently closed circular DNA  
*Bianca C, Sidhartha E, Tiribelli C, El-Khobar KE, Sukowati CHC*
- 885 Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma  
*Zane KE, Nagib PB, Jalil S, Mumtaz K, Makary MS*

**MINIREVIEWS**

- 896 Saving time and effort: Best practice for adapting existing patient-reported outcome measures in hepatology  
*Alrubaiy L, Hutchings HA, Hughes SE, Dobbs T*
- 911 Loco-regional treatment of hepatocellular carcinoma: Role of contrast-enhanced ultrasonography  
*Inzerillo A, Meloni MF, Taibbi A, Bartolotta TV*
- 923 Benign focal liver lesions: The role of magnetic resonance imaging  
*Gatti M, Maino C, Tore D, Carisio A, Darvizeh F, Tricarico E, Inchingolo R, Ippolito D, Faletti R*
- 944 Pediatric acute viral hepatitis with atypical variants: Clinical dilemmas and natural history  
*Sarma MS, Ravindranath A*

**ORIGINAL ARTICLE****Basic Study**

- 956 Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis  
*Zhang CY, Yang M*

**Case Control Study**

- 972 Innovations in education: A prospective study of storytelling narratives to enhance hepatitis C virus knowledge among substance users  
*Talal AH, Ding YX, Markatou M*

**Retrospective Study**

- 984 Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database  
*Dhaliwal A, Dhindsa B, Ramai D, Sayles H, Chandan S, Rangray R*

- 992 Angle of covered self-expandable metallic stents after placement is a risk factor for recurrent biliary obstruction

*Tanoue K, Maruyama H, Ishikawa-Kakiya Y, Kinoshita Y, Hayashi K, Yamamura M, Ominami M, Nadatani Y, Fukunaga S, Otani K, Hosomi S, Tanaka F, Kamata N, Nagami Y, Taira K, Watanabe T, Fujiwara Y*

#### Observational Study

- 1006 Dietary phytochemical consumption is inversely associated with liver alkaline phosphatase in Middle Eastern adults

*Darabi Z, Webb RJ, Mozaffari-Khosravi H, Mirzaei M, Davies IG, Khayyat-zadeh SS, Mazidi M*

#### Prospective Study

- 1016 Prospective validation to prevent symptomatic portal vein thrombosis after liver resection

*Yoshida N, Yamazaki S, Masamichi M, Okamura Y, Takayama T*

### SYSTEMATIC REVIEWS

- 1025 Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis

*Cianci N, Subhani M, Hill T, Khanna A, Zheng D, Sheth A, Crooks C, Aithal GP*

### CASE REPORT

- 1038 Biliary obstruction following transjugular intrahepatic portosystemic shunt placement in a patient after liver transplantation: A case report

*Macinga P, Gogova D, Raupach J, Jarosova J, Janousek L, Honsova E, Taimr P, Spicak J, Novotny J, Peregrin J, Hucl T*

### LETTER TO THE EDITOR

- 1047 Reply to "Six-minute walking test performance is associated with survival in cirrhotic patients" to the editor

*Malaguti C, Mourão-Junior CA, Chebli JM*

- 1050 Role of biliary complications in chronic graft rejection after living donor liver transplantation

*Obed A, Bashir A, Jarrad A, Fuzesi L*

**ABOUT COVER**

Editorial Board Member of *World Journal of Hepatology*, Francesco Bellanti, MD, PhD, Doctor, Associate Professor, Department of Medical and Surgical Sciences, University of Foggia, Foggia 71122, Italy. francesco.bellanti@unifg.it

**AIMS AND SCOPE**

The primary aim of *World Journal of Hepatology (WJH, World J Hepatol)* is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJH* mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

**INDEXING/ABSTRACTING**

The *WJH* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 Journal Citation Indicator (JCI) for *WJH* as 0.52. The *WJH*'s CiteScore for 2021 is 3.6 and Scopus CiteScore rank 2021: Hepatology is 42/70.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Yi-Xuan Cai*, Production Department Director: *Xiang Li*, Editorial Office Director: *Xiang Li*.

**NAME OF JOURNAL**

*World Journal of Hepatology*

**ISSN**

ISSN 1948-5182 (online)

**LAUNCH DATE**

October 31, 2009

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Nikolaos Pylsopoulos, Ke-Qin Hu, Koo Jeong Kang

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-5182/editorialboard.htm>

**PUBLICATION DATE**

May 27, 2022

**COPYRIGHT**

© 2022 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

## Case Control Study

# Innovations in education: A prospective study of storytelling narratives to enhance hepatitis C virus knowledge among substance users

Andrew H Talal, Yu-Xin Ding, Marianthi Markatou

**Specialty type:** Gastroenterology and hepatology**Provenance and peer review:** Unsolicited article; Externally peer reviewed.**Peer-review model:** Single blind**Peer-review report's scientific quality classification**Grade A (Excellent): A, A  
Grade B (Very good): B  
Grade C (Good): 0  
Grade D (Fair): 0  
Grade E (Poor): E**P-Reviewer:** Granito A, Italy; Liu CH, Taiwan; Tanaka N, Japan**Received:** January 5, 2022**Peer-review started:** January 5, 2022**First decision:** February 8, 2022**Revised:** February 21, 2022**Accepted:** April 20, 2022**Article in press:** April 20, 2022**Published online:** May 27, 2022**Andrew H Talal**, Department of Medicine, University at Buffalo, State University of New York, Buffalo, NY 14203, United States**Yu-Xin Ding, Marianthi Markatou**, Department of Biostatistics, University at Buffalo, State University of New York, Buffalo, NY 14214, United States**Corresponding author:** Andrew H Talal, MD, Professor, Department of Medicine, University at Buffalo, State University of New York, 875 Ellicott Street, UB CTRC 6090, Buffalo, NY 14203, United States. [ahatalal@buffalo.edu](mailto:ahatalal@buffalo.edu)

## Abstract

### BACKGROUND

Even though substance users have the highest hepatitis C virus (HCV) burden, many lack knowledge about the infection. Lack of knowledge is an important obstacle to pursuing HCV care. Although printed materials are conventionally utilized to disseminate HCV-related knowledge, narrative story-telling videos may be an alternative. Data are extremely limited, however, in the ability of storytelling videos to increase HCV knowledge among substance users. In this study, we hypothesized that a story-telling narrative video would increase substance user's immediate and 1-month HCV-related knowledge compared to a printed format.

### AIM

To assess immediate and 1-month HCV-related knowledge retention among substance users comparing education delivered *via* a storytelling narrative video compared to a printed format.

### METHODS

We conducted a prospective matched, case-control study among substance users actively prescribed buprenorphine enrolled from two sites. The intervention site received the video and the control site, the brochure. Participants ( $n = 176$ ) were matched on age, gender, and race. We obtained extensive patient and stakeholder input on the video's design, validated the video's content, and developed a recruitment plan to guide participant enrollment. Knowledge was assessed by administration of a 25-item instrument immediately before, immediately after, or one month after the intervention. Data were analyzed using nonparametric and

generalized linear mixed-effects models.

## RESULTS

We recruited a total of 176 substance users, 90 and 86 individuals, from each site, respectively. One-month follow up occurred in 92% and 94% of enrollees in the control and intervention groups, respectively. In comparison with the pre-intervention scores, immediate knowledge recall increased significantly for both the intervention ( $P < 0.0001$ ) and control ( $P < 0.0001$ ) groups. Multivariate modeling revealed a significant improvement in HCV-related knowledge and retention ( $P = 0.033$ ) among participants who viewed the storytelling video.

## CONCLUSION

Storytelling narratives emphasizing HCV education appear to be an effective method to increase HCV-related knowledge among substance users. They should become an educational cornerstone to promote HCV management among this population.

**Key Words:** Hepatitis C virus education; Hepatitis C Virus; Hepatitis C virus knowledge; Persons with opioid use disorder; Decision-making in healthcare

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Despite high hepatitis C virus (HCV) burden, people with opioid use disorder (PWOUD) frequently lack knowledge about HCV. Printed brochures are the conventional method of HCV knowledge dissemination, although storytelling narrative videos have attributes that suggest they may be more effective. In this study, we assessed HCV knowledge improvement among PWOUD comparing a storytelling narrative video to a written brochure. Among 176 PWOUD, we found that immediate HCV-related knowledge recall was significantly increased by both methods. Multivariate modeling revealed a significant improvement in HCV-related knowledge and retention among intervention participants. In conclusion, storytelling narratives effectively improve HCV-related knowledge among PWOUD.

**Citation:** Talal AH, Ding YX, Markatou M. Innovations in education: A prospective study of storytelling narratives to enhance hepatitis C virus knowledge among substance users. *World J Hepatol* 2022; 14(5): 972-983

**URL:** <https://www.wjgnet.com/1948-5182/full/v14/i5/972.htm>

**DOI:** <https://dx.doi.org/10.4254/wjh.v14.i5.972>

## INTRODUCTION

Hepatitis C virus (HCV) is an extremely common chronic blood-borne virus pathogen and is principally transmitted through injection drug use[1]. HCV is a leading cause of morbidity and mortality among persons with opioid use disorder (PWOUD) reaching as high as 80% with an annual incidence ranging from 16% to 42%[2,3]. Untreated HCV can progress to cirrhosis, end-stage liver disease and hepatocellular carcinoma. Recently, direct acting antivirals (DAAs) have revolutionized HCV treatment. DAAs are all oral medications, administered for 2 to 3 mo, with nearly universal efficacy and minimal side effects[4]. In fact, recent data have documented the importance of simultaneous treatment of opioid use disorder and HCV; treatment for both entities results in improved treatment adherence and a reduction in substance use[5,6]. Given the importance and burden of HCV, the US Preventative Services Task Force recently revised HCV screening recommendations[7]. Currently, all individuals aged 18 to 79 years should undergo a one-time HCV antibody test with more frequent assessments among high-risk individuals, such as PWOUD. In addition, HCV elimination by 2030 has been promulgated in the United States and globally[8,9]. To achieve HCV elimination objectives, however, we need to address HCV knowledge gaps among PWOUD. Only fifty percent of HCV-infected PWOUD know their infection status, and many underestimate the urgent need for HCV treatment[10,11]. Furthermore, substance users have recently been shown to have low to moderate health literacy levels[12-14], and health literacy is an extremely important predictor of health status[15]. Thus, interventions to increase HCV-related knowledge targeted to PWOUD are required to achieve HCV elimination objectives[16].

Lack of consideration of health literacy status often complicates patient-provider communication especially among low health literacy populations. In terms of written material, a typical method of health knowledge dissemination, readability at an appropriate grade level is an important consideration. One study found that internet-derived liver disease information is written at a higher readability score than is recommended, an important potential source of misinformation among liver disease patients[17]. In the area of HCV, several studies, which largely utilized in-person delivery of

didactic sessions, have illustrated that educational interventions can improve HCV knowledge[18-22], screening[23,24], and linkage-to-care[25,26]. These methods, however, can be burdensome in terms of cost, resources, and time requirements. Alternatively, computerized health platforms appear to facilitate health education dissemination ubiquitously and at a reduced cost compared to in-person lectures[27-30]. While a few studies have assessed their educational value, these platforms largely disseminate facts or schematics about HCV or liver diseases using an instructional or didactic framework. While informative, these knowledge dissemination methods may not resonate with substance users.

Narrative videos, defined as “first-person stories about experiences with illness and its personal consequences”, have been shown to be more persuasive at behavioral change than written narratives or didactic lectures[31,32]. Although data are limited, narratives that address healthcare issues may be a particularly effective method to increase knowledge among PWOD. A systematic review concluded that videos detailing story-based messages were more persuasive than non-narrative videos[32]. To improve HCV-related knowledge dissemination to substance users, we sought to develop and to validate an educational intervention targeted to PWOD utilizing narratives presented in a video format. Virtual communication strategies, such as videos, are easily conducive to storytelling and can employ an expanded repertoire of communication styles in comparison with printed material. As storytelling is a particularly effective pedagogical method amongst PWOD, our objective was to assess whether a video would improve PWOD’s immediate information recall and one-month knowledge retention compared with a written brochure.

---

## MATERIALS AND METHODS

---

### **Study design**

We conducted a prospective case-control study to assess immediate and longer-term knowledge retention comparing two different educational delivery methods. The control arm received an HCV educational brochure, and in the intervention arm, participants viewed a twelve-minute educational video, which contained the same information as was included in the brochure. Participants in each arm also completed the same knowledge assessments at the same time points: prior to reading the brochure or viewing the video, immediately following the interventions (*i.e.*, brochure or video), and within 30 +/- 14 d of the initial time point.

Participants were recruited according to a recruitment plan (see below) between January and October, 2020 from community health organizations that provide treatment services, specifically buprenorphine, for opioid use disorder. Each site is under the auspices of New York State Office of Addiction Services and Supports (OASAS) and has adopted a harm reduction approach, which refers to policies and programs designed to reduce drug-use associated harm; the goal is harm prevention from drug use rather than prevention of drug use itself[33,34].

Participant inclusion criteria included individuals at least 18 years old, who were currently prescribed buprenorphine, and who spoke English as their primary language.

### **Patient consent statement**

The study was approved by the University at Buffalo and the Catholic Health Service Institutional Review Boards, and all patients provided informed consent prior to participating in any study related activities.

### **Video, brochure, and knowledge assessments**

**Brochure:** As the American Liver Foundation is a principal source for patient-oriented printed materials and handouts on a variety of liver diseases, we utilized their instructional brochure for information about HCV ([Supplementary material](#)).

**Video:** Patients provided the initial concept of a video and enabled us to identify important HCV-related knowledge gaps in the areas of diagnosis, pathogenesis, transmission, screening, treatment, and long-term infection consequences. We subsequently reviewed and expanded the identified topics with opioid treatment program staff. Staff also described knowledge dissemination methods for PWOD, such as emphasizing that visuals are extremely important and that human stories are “priceless”, consistent with prior literature[35]. The narrative within the video contains a storyline with a beginning, middle and an end where the storyline conflict is brought to conclusion[36]. Based upon acquired feedback, we incorporated visualization strategies into the video, such as emphasizing main points in words or captions strategically situated within the image frame, to underscore the important pedagogical value.

We next reviewed the brochure to ensure that the same information would be presented in both educational formats and subsequently engaged a professional screenwriter to develop the video script. Multiple iterations of the script were reviewed to ensure the accuracy of the educational information. After filming and editing, a draft version of the video was reviewed and finalized by the study team and content validity was assessed as described below. The final video is available at: <https://drive>.

[google.com/file/d/1mrJbXpRI7YrqbhoPH3sUphOTz2TNgc0e/view?usp=sharing](https://drive.google.com/file/d/1mrJbXpRI7YrqbhoPH3sUphOTz2TNgc0e/view?usp=sharing).

**Knowledge assessment design and assessment of content validity:** Details related to the design of the knowledge assessment and the assessment of its content validity are described in the [Supplementary material](#).

### **Recruitment plan development**

We matched participants recruited from each site on age, gender, and race to control for potentially unmeasured confounding factors. We initially evaluated the demographics of all individuals from both sites. After considering the inclusion criteria and those with complete demographic information, the intervention site had 1647 potential participants and the control site had 526 potential participants. The two sites were randomly assigned to either the intervention or the control.

We next used gender, age and race to perform 1:1 exact matching of individuals from the two sites utilizing the “Match” function (R package, version 3.5.3)[37]. Given the paucity of nonwhite individuals, potential participants were categorized into two groups: white and other races. Age was also classified into two groups: age  $\leq 39$  or  $> 39$  years. The algorithm identified 7928 exactly matched pairs in which 508 pairs were unique individuals from the control site. According to the distribution of matched individuals, each site was requested to recruit 90 participants according to the proportion in each category (See [Supplementary material](#) for sample size calculation and [Supplementary Table 3](#) for the recruitment plan).

### **Recruitment**

Site staff initially identified potentially eligible participants on the clinical schedule and then assessed potential participant’s interest in study participation. If interest was affirmed, research staff next obtained informed consent. Afterwards, we verified participant demographics, and they completed the pre-test assessment. Participants then read the brochure or watched the video, and they promptly completed the knowledge assessment a second time (*i.e.*, post-test assessment). Thirty days afterwards, we requested that participants complete the third knowledge assessment (1 mo post-test assessment). We compensated participants \$40 for completion of all assessments. After the COVID-19 pandemic, we recruited approximately 20% of participants *via* telephone.

### **Statistical analysis**

We performed complete-case analysis since less than 5% of the data were missing. We initially calculated the participants’ response scores obtained on each knowledge assessment; each correctly answered item garnered one credit. The improvement in knowledge attributable to the intervention was defined as the difference in scores between post- and pre- educational intervention assessments. We used the Wilcoxon signed-rank test to compare each participants’ pre- and post-educational intervention scores[38]. We applied the Wilcoxon rank sum test to compare the improvements in participants’ scores between post- and pre-educational intervention tests between the two sites. All significance tests were performed by using R version 3.5.3[37].

Our outcome variable is the number of correct answers provided by each participant. To incorporate the time effect into our analysis and since the outcome data are counts, we used a generalized linear mixed-effects model. The fixed effects include gender, race, educational intervention, timepoint (post-education and one-month follow-up) and clinic by visit interaction with all variables measured on a categorical scale, and we incorporated age in the model. Race was categorized into two levels (white *vs* other races), considering the small sample size of the nonwhite population. We modeled the pre-education test scores through model inclusion as the baseline (BL) value,  $X_{BL,i}$  associated with the  $i^{\text{th}}$  study participant to adjust for differences in participants’ educational levels and other potential unmeasured confounders that might have affected baseline scores. The random effects corresponded to unknown subject effects and was captured the within-subject variability. The outcome data were assumed to be Poisson distributed and the ln (log link with base e) was used in the generalized linear mixed-effects model (SAS Version 9.4, SAS Corporation, Cary, NC).

## **RESULTS**

### **Demographic characteristics**

We recruited 90 and 86 participants from the control and intervention sites, respectively, according to recruitment plan specifications. Participant demographics are illustrated in [Table 1](#).

### **Participant questionnaire completion**

We requested that each participant complete a knowledge assessment immediately preceding and upon conclusion of the educational intervention. They also completed the same assessment one-month after the intervention to investigate longer-term knowledge retention. The proposed and actual numbers of study participants who were recruited and their response rates, as assessed by completion of the pre-,

**Table 1 Demographic characteristics of study participants**

Intervention	Brochure	Video
<i>n</i>	90	86
Age		
Median (IQR)	41 (18)	40(18)
Mean (SD)	43 (11)	41(12)
Gender		
Female	55 (61%)	51 (59%)
Male	35 (39%)	35 (41%)
Race		
White	76 (84%)	74 (86%)
Other races	14 (16%)	12 (14%)

IQR: Interquartile ratio; SD: Standard deviation.

post-, and one-month follow up assessments, are illustrated (Supplementary Table 3).

In terms of response rates, all 90 participants in the control and 86 participants in the intervention arms completed both the pre- and post-educational intervention assessments. In terms of one-month follow-up response rates, 7 control and 5 intervention participants did not complete the assessment.

**Descriptive and graphical analysis**

**Pre- and post-educational intervention results:** For participants who observed the video, post-educational intervention scores improved significantly in comparison with pre-intervention scores (the value of the Wilcoxon signed-rank test is  $V = 2848.5, P < 0.0001$ ). For control participants, significant differences between the post- and pre-intervention scores are also observed ( $V = 2816, P < 0.0001$ ).

**Improvement in educational intervention results:** We also illustrate the improvements in the scores comparing the post- and pre-intervention assessments graphically (Figure 1). The significant improvement ( $W = 4817$  and  $P = 0.0047$ ) in test scores comparing each intervention is shown[39]. The improvement in test scores was greater among participants in the intervention arm as compared to the control arm.

**One-month education retention results:** The raw mean of participants’ scores on pre- and post-educational intervention as well as on the one-month follow up assessments are illustrated (Figure 2). We observed substantial improvements from the pre-intervention to the post-intervention assessments in both clinics accompanied by a slight reduction in the scores obtained on the one-month follow-up assessments. The intervention site was observed to have a relatively higher improvement in the post-intervention assessment and improved knowledge retention on the one-month follow-up assessment.

**Impact of COVID-19**

Due to COVID-19-related restrictions, some of the intervention site participants were recruited *via* phone. Data indicate that pre-education scores are approximately similar comparing participants recruited in-person with those *via* phone (Table 2).

**Multivariate modeling results**

We utilized a generalized mixed-effects model to model the data. Table 3 shows the type III tests results for fixed effects, which utilizes the exact F tests. Modeling results revealed that the type of educational intervention, specifically the video, had a significant effect on the improvement in HCV-related knowledge and retention ( $P = 0.0326$ ) as compared to the brochure (Table 3). The age, gender, race, and the interaction term of the intervention and time point are not significant. The overall time point effect is significant ( $P = 0.0004$ ), and within each clinic, the least square mean differences between one-month follow up and post-education test scores are  $-0.0634$  ( $P = 0.0357$ ) and  $-0.0908$  ( $P = 0.0033$ ) for the video and brochure, respectively, which indicates a  $0.0634$  decrease in test score on the one-month follow-up compared to the post-intervention assessment for the video group and  $0.0908$  decrease in the brochure group. The baseline score, *i.e.*, the number of correct responses prior to any educational intervention, has a significant impact on the post-intervention and one-month follow-up test scores with  $P < 0.0001$ . We refer to this variable as the baseline score; its inclusion in the model adjusts for any pre-existing knowledge differences that might exist between clinics.

**Table 2** Descriptive statistics associated with pre-education scores of individuals recruited on site and those recruited *via* phone

Pre-education score	Recruitment method		Intervention site total (n = 86)
	On-site (n = 50)	Via phone (n = 36)	
Mean (SD)	19.3 (2.27)	18.6 (2.51)	19.0 (2.38)
Median (Min, Max)	19.0 ([15, 24])	18.5 ([13, 24])	19.0 ([13, 24])

SD: Standard deviation.


**Table 3** Results of type III tests of fixed effects

Effect	F value	P value
Age	0.92	0.3378
Gender	0	0.9710
Race <sup>1</sup>	2.62	0.1072
Educational intervention <sup>2</sup>	4.65	0.0326
Time point <sup>3</sup>	13.01	0.0004
Educational intervention × time point	0.41	0.5219
Baseline score (Pre-education score)	36.22	< 0.0001

<sup>1</sup>Race is categorized into two levels: white and other races.

<sup>2</sup>Educational intervention indicates either the intervention or the control group.

<sup>3</sup>Time point indicates the post-education or one-month follow up assessment.




DOI: 10.4254/wjh.v14.i5.972 Copyright ©The Author(s) 2022.

**Figure 1** The distribution of improvement in scores calculated as the pre-intervention subtracted from the post-intervention for both interventions are illustrated in the violin plot wrapping a boxplot. The box extends from the 25<sup>th</sup> to the 75<sup>th</sup> percentile with lines extending outward depicting the smallest value within 1.5 times the interquartile range (IQR) below the 25<sup>th</sup> percentile and largest value within 1.5 times the IQR above the 75<sup>th</sup> percentile. The dark line in the middle of the box illustrates the median values. Peach indicates the control site (brochure) and blue (video) the intervention site. The violin displays the density plot of the values, where the width indicates the frequency.

## DISCUSSION

In this study, we developed and validated an HCV educational narrative video targeted to PWOUD. Each narrative emphasizes HCV-related knowledge, and we utilized technological enhancements to underscore important points. Utilizing a case-control design, we subsequently enrolled PWOUD on buprenorphine from two separate sites, one received the intervention and the other was a control site. Although both the video and the printed formats increased immediate recall and retention of HCV-related knowledge, gains were significantly greater amongst the participants who viewed the video.



**Figure 2** Illustrated are mean scores for the assessments obtained pre- and post- as well as after one month after the video (blue) and brochure (red/peach) educational interventions.

Substance users have a method for information spread amongst themselves, referred to as the “peer pipeline”, that compromised our ability to randomize at the patient level[40,41]. To minimize bias between the two sites, we matched participants on demographic factors including age, gender, and race. Several attributes between the sites were similar, including staffing ratios, treatment philosophy, and therapeutic approaches, since both sites are under the direction of the same state agency (OASAS), which regulates and funds medications for opioid use disorder (MOUD) dispensed in New York State.

Education about HCV and the benefits of DAAs is essential to promote PWOUD pursuit of HCV treatment and is required to achieve HCV elimination objectives[8,9]. Low to moderate health literacy in PWOUD and misinformation concerning basic facets of liver disease among many liver disease patients are important considerations in the design of educational interventions[12-14,42]. While several prior studies have shown knowledge increases after HCV education, these studies enrolled different populations; some recruited hospital-based clinic patients while others recruited PWOUD[2,20,22,25,28]. In a study conducted in PWOUD, no differences were identified in viral hepatitis-related knowledge between those undergoing a motivational interviewing style compared with standard counseling[20]. Another study that reported low health literacy among PWOUD illustrated that personalized educational communication techniques result in increased knowledge[13].

Addressing HCV-related knowledge gaps requires innovative and targeted educational approaches. Storytelling narrative videos are a potential alternative to conventional in- person instructional lectures, although the latter has been evaluated in most HCV-related published work to date[27-30,43]. One study used an I-pad platform to deliver educational instruction about HCV[30]. Another study developed a didactic video about liver disease, and a third developed a short didactic video message designed to persuade PWOUD to pursue HCV surveillance[27,28]. Additionally, Hochstatter *et al.* identified no differences in HCV testing uptake between intervention and control participants who utilized HCV-related educational content and functionality added to an m-health substance use disorder relapse prevention platform[29,43]. mHealth systems developed to date designed to educate PWOUD about HCV appear to largely utilize a didactic approach complemented by linkage to community and government-based resources as opposed to narrative stories.

Multiple, as opposed to single, interventions have shown promise to improve health information comprehension by low literacy populations[44,45]. Multimodal presentations, combined with storytelling narratives, allow for participant transportation into the narrative, defined as “the audience’s immersion in the imagined world”[36,46]. The degree of the viewer’s emotional engagement with the narrative and the identification with the protagonist are important determinants of narrative’s persuasiveness for behavioral modification[47,48]. Storytelling is used extensively to promote persuasiveness in healthcare[31,49,50], and video narratives have been shown to be more persuasive at health promotion than written narratives or instructional or didactic videos[32,51]. Future investigation should evaluate whether different educational modalities will lead to improvements in PWOUD pursuit of HCV management.

Increasing PWOUD pursuit of HCV diagnosis and treatment can accrue significant benefits. Besides improvements in patient-reported outcomes, such as fatigue[52], an HCV cure decreases the risk of progression to cirrhosis and hepatocellular carcinoma[53]. Furthermore, as alcohol intake has been shown to be an independent predictor of hepatic cirrhosis and mortality in HCV-infected individuals [54], alcohol cessation education is required for all HCV-infected individuals.

Extensive stakeholder input on the intervention design, the comparison group, the construct validation, and study design are investigative strengths. Additionally, we minimized potential bias by

conducting the study in geographically separated sites and through matching participants on available demographics. We were limited by the inability to conduct a randomized trial given the research infrastructure present, the available resources, and the existence of the peer pipeline. We were, unfortunately, unable to collect information on participant's education levels or on their substance use treatment course. To address these limitations, we included the baseline questionnaire responses as a dependent variable in the multivariate modeling. The inclusion of the pre-education test score controls for differences, for example, in education levels between the two sites.

HCV-related education is critical to promote PWOD screening and linkage-to-care. PWOD have the highest HCV prevalence and incidence, and highly-effective DAAs decrease HCV-associated morbidity and mortality[4]. HCV treatment has also been shown to diminish or stabilize substance use, to improve retention in OUD treatment and to increase medication adherence[6,55]. MOUD also reduces risk of HCV reinfection[56]. To maximize the effectiveness of HCV educational interventions targeted to PWOD, future investigation should evaluate knowledge dissemination and engagement among PWOD comparing educational formats (*i.e.*, storytelling narratives vs. instructional/didactic formats) that incorporate multimodal technologies.

---

## CONCLUSION

Education improves HCV-related knowledge among PWOD. Storytelling narratives significantly improve knowledge retention compared to written instructional brochures. They should become a cornerstone to promote HCV knowledge among PWOD.

## ARTICLE HIGHLIGHTS

### **Research background**

Despite high hepatitis C virus (HCV) incidence and prevalence, many substance users lack basic knowledge about HCV infection and its consequences.

### **Research motivation**

HCV education targeted to persons with opioid use disorder (PWOD) has largely utilized conventional written approaches through brochures and pamphlets. Innovative approaches, such as storytelling narrative videos, may be more appealing resulting in increased knowledge ascertainment and retention. Data are limited though on the ability of narrative videos to increase knowledge among substance users.

### **Research objectives**

To assess immediate and 1 mo HCV knowledge recall and retention among substance users comparing education delivered *via* a storytelling narrative video to a written brochure.

### **Research methods**

PWOD on medication for opioid use disorder were prospectively enrolled from two sites, one site reviewed the written brochure and the other site viewed the video. Participants ( $n = 176$ ), matched on age, race, and gender, completed the same knowledge assessments immediately prior to and upon completion of reading the brochure or watching the video. The same assessment was completed one month later to evaluate longer-term knowledge retention. We utilized generalized linear mixed-effects models to analyze the data.

### **Research results**

We observed that both interventions significantly increased immediate and longer-term HCV-related knowledge. Multivariate modeling revealed significant improvements in HCV-related knowledge and retention ( $P = 0.033$ ) among participants who viewed the storytelling narrative video.

### **Research conclusions**

Storytelling narrative videos appear to be an effective strategy to increase HCV-related knowledge among PWOD. Whether videos are an effective method to change behavior requires further investigation.

### **Research perspectives**

Given their ability to include multimodal techniques and their ease of distribution, storytelling narrative videos may do well as an educational cornerstone to disseminate HCV-related knowledge to vulnerable populations, such as PWOD, as well as to the general public.

---

## ACKNOWLEDGEMENTS

---

We acknowledge the contributions of the administrative, counseling, and clinical staff at University of Rochester Strong Recovery Chemical Dependency for input on the educational topics of interest. We also acknowledge the staff at Catholic Health Services St. Vincent Health Center (Paul Updike MD, Judith Galante, RN, and Martha Gloss) and at Best-Self Behavioral Health (Stacie Capozzi, June Cline, and Amanda Arnone) for their assistance with patient recruitment and data collection. We also acknowledge Justin Bondi, Dr. Joe Huntz, James Huntz, and Dr. Mohammed Tahir for their assistance with designing and production of the instructional video. We also acknowledge Darlene Meyer and Cliff Minter, MPH for assistance with data collection, Joshua Osmanski for assistance with manuscript drafting, and Professor Melanie Green for helpful discussions.

---

## FOOTNOTES

---

**Author contributions:** Talal AH conceived of the study, obtained funding, supervised data collection, wrote and revised the manuscript; Markatou M obtained funding, designed the study and supervised the analysis, wrote and revised the manuscript; Ding Y designed the study and performed the analysis, wrote and revised the manuscript; all authors have read and approve the final manuscript.

**Supported by** the Investigator-Initiated Grant from Merck Inc, No. MISP# 57252; the Troup Fund of the Kaleida Health Foundation; and the Patient-Centered Outcomes Research Institute Award, IHS-1507-31640.

**Institutional review board statement:** The study was reviewed and approved by the University at Buffalo (Approval No. 00002677).

**Clinical trial registration statement:** ClinTrials.gov Registration No. NCT04204447. Date of initial posting: December 19, 2019.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** None of the other authors have any potential conflicts.

**Data sharing statement:** Data are available from the corresponding author at [ahtalal@buffalo.edu](mailto:ahtalal@buffalo.edu) upon reasonable request.

**STROBE statement:** The manuscript has been prepared and revised according to the STROBE Statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** United States

**ORCID number:** Andrew H Talal [0000-0002-5565-7515](https://orcid.org/0000-0002-5565-7515); Yu-Xin Ding [0000-0002-1359-1247](https://orcid.org/0000-0002-1359-1247); Marianthi Markatou [0000-0002-1453-8229](https://orcid.org/0000-0002-1453-8229).

**S-Editor:** Wang LL

**L-Editor:** A

**P-Editor:** Wang LL

---

## REFERENCES

---

- 1 Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013. *Clin Infect Dis* 2016; **62**: 1287-1288 [PMID: [26936668](https://pubmed.ncbi.nlm.nih.gov/26936668/) DOI: [10.1093/cid/ciw111](https://doi.org/10.1093/cid/ciw111)]
- 2 Zeremski M, Dimova RB, Zavala R, Kritz S, Lin M, Smith BD, Zibbell JE, Talal AH. Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance. *J Addict Med* 2014; **8**: 249-257 [PMID: [24820257](https://pubmed.ncbi.nlm.nih.gov/24820257/) DOI: [10.1097/adm.0000000000000041](https://doi.org/10.1097/adm.0000000000000041)]
- 3 Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, Vlahov D, Strathdee SA, Hudson SM, Kerndt P, Des Jarlais D, Williams IT. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. *Clin Infect Dis* 2008; **46**: 1852-1858 [PMID: [18462109](https://pubmed.ncbi.nlm.nih.gov/18462109/) DOI: [10.1086/588297](https://doi.org/10.1086/588297)]
- 4 Alawad AS, Auh S, Suarez D, Ghany MG. Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s

- Antigen. *Clin Gastroenterol Hepatol* 2020; **18**: 700-709.e3 [PMID: 31323381 DOI: 10.1002/hep.31060]
- 5 **Springer SA**, Del Rio C. Co-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes! *Clin Infect Dis* 2020; **71**: 1723-1725 [PMID: 32011653 DOI: 10.1093/cid/ciaa111]
  - 6 **Rosenthal ES**, Silk R, Mathur P, Gross C, Eyasu R, Nussdorf L, Hill K, Brokus C, D'Amore A, Sidique N, Bijole P, Jones M, Kier R, McCullough D, Sternberg D, Stafford K, Sun J, Masur H, Kottlil S, Kattakuzhy S. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs. *Clin Infect Dis* 2020; **71**: 1715-1722 [PMID: 32009165 DOI: 10.1093/cid/ciaa105]
  - 7 **US Preventive Services Task Force**; Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Donahue K, Doubeni CA, Epling JW Jr, Kubik M, Ogedegbe G, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. *JAMA* 2020; **323**: 970-975 [PMID: 32119076 DOI: 10.1001/jama.2020.1123]
  - 8 **US Department of Health and Human Services**. Viral Hepatitis National Strategic Plan for the United States: a Roadmap to Elimination (2021-2025) Washington, DC. [cited 20 January 2022]. Available from: <https://www.hhs.gov/hepatitis/viral-hepatitis-national-strategic-plan/index.html>
  - 9 **World Health Organization**. Combating Hepatitis B and C to Reach Elimination by 2030: Advocacy Brief. Geneva: World Health Organization, 2016 Contract No. WHO/HIV/2016.04
  - 10 **Denniston MM**, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. *Hepatology* 2012; **55**: 1652-1661 [PMID: 22213025 DOI: 10.1002/hep.25556]
  - 11 **Barua S**, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. *Ann Intern Med* 2015; **163**: 215-223 [PMID: 26120969 DOI: 10.7326/m15-0406]
  - 12 **Degan TJ**, Kelly PJ, Robinson LD, Deane FP. Health literacy in substance use disorder treatment: A latent profile analysis. *J Subst Abuse Treat* 2019; **96**: 46-52 [PMID: 30466548 DOI: 10.1016/j.jsat.2018.10.009]
  - 13 **Dahlman D**, Ekefall M, Garpenhag L. Health Literacy among Swedish Patients in Opioid Substitution Treatment: A Mixed-Methods Study. *Drug Alcohol Depend* 2020; **214**: 108186 [PMID: 32721789 DOI: 10.1016/j.drugalcdep.2020.108186]
  - 14 **Degan TJ**, Kelly PJ, Robinson LD, Deane FP, Smith AM. Health literacy of people living with mental illness or substance use disorders: A systematic review. *Early Interv Psychiatry* 2021; **15**: 1454-1469 [PMID: 33254279 DOI: 10.1111/eip.13090]
  - 15 **Weiss, BD**. Health literacy and patient safety: Help patients understand 2nd edition ed. Chicago, IL: American Medical Association; 2007
  - 16 **Scott N**, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, Thompson A, Hellard ME. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. *Int J Drug Policy* 2017; **47**: 107-116 [PMID: 28797497 DOI: 10.1016/j.drugpo.2017.07.006]
  - 17 **Gulati R**, Nawaz M, Pysopoulos NT. Comparative analysis of online patient education material pertaining to hepatitis and its complications. *Eur J Gastroenterol Hepatol* 2016; **28**: 558-566 [PMID: 26982338 DOI: 10.1097/MEG.0000000000000588]
  - 18 **Dunn KE**, Saulsgiver KA, Patrick ME, Heil SH, Higgins ST, Sigmon SC. Characterizing and improving HIV and hepatitis knowledge among primary prescription opioid abusers. *Drug Alcohol Depend* 2013; **133**: 625-632 [PMID: 24051063 DOI: 10.1016/j.drugalcdep.2013.08.007]
  - 19 **Zeremski M**, Zavala R, Dimova RB, Chen Y, Kritz S, Sylvester C, Brown LS Jr, Talal AH. Improvements in HCV-related Knowledge Among Substance Users on Opioid Agonist Therapy After an Educational Intervention. *J Addict Med* 2016; **10**: 104-109 [PMID: 26881485 DOI: 10.1097/adm.0000000000000196]
  - 20 **Larios SE**, Masson CL, Shopshire MS, Hettema J, Jordan AE, McKnight C, Young C, Khalili M, Seewald RM, Min A, Hengl N, Sorensen JL, Des Jarlais DC, Perlman DC. Education and counseling in the methadone treatment setting improves knowledge of viral hepatitis. *J Subst Abuse Treat* 2014; **46**: 528-531 [PMID: 24462241 DOI: 10.1016/j.jsat.2013.10.012]
  - 21 **Marinho RT**, Costa A, Pires T, Raposo H, Vasconcelos C, Polónia C, Borges J, Soares M, Vilar G, Nogueira AM; LIGUE-C Investigators. A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care. *BMC Infect Dis* 2016; **16**: 565 [PMID: 27733137 DOI: 10.1186/s12879-016-1883-6]
  - 22 **Surjadi M**, Torruellas C, Ayala C, Yee HF Jr, Khalili M. Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. *Dig Dis Sci* 2011; **56**: 213-219 [PMID: 20972850 DOI: 10.1007/s10620-010-1455-3]
  - 23 **Arain A**, De Sousa J, Corten K, Verrando R, Thijs H, Mathei C, Buntinx F, Robaey G. Pilot Study: Combining Formal and Peer Education with FibroScan to Increase HCV Screening and Treatment in Persons who use Drugs. *J Subst Abuse Treat* 2016; **67**: 44-49 [PMID: 27296661 DOI: 10.1016/j.jsat.2016.04.001]
  - 24 **Norton BL**, Voils CI, Timberlake SH, Hecker EJ, Goswami ND, Huffman KM, Landgraf A, Naggie S, Stout JE. Community-based HCV screening: knowledge and attitudes in a high risk urban population. *BMC Infect Dis* 2014; **14**: 74 [PMID: 24512462 DOI: 10.1186/1471-2334-14-74]
  - 25 **Gupta K**, Romney D, Briggs M, Benker K. Effects of a brief educational program on knowledge and willingness to accept treatment among patients with hepatitis C at inner-city hospitals. *J Community Health* 2007; **32**: 221-230 [PMID: 17696047 DOI: 10.1007/s10900-007-9046-8]
  - 26 **Lubega S**, Agbim U, Surjadi M, Mahoney M, Khalili M. Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. *Liver Int* 2013; **33**: 999-1007 [PMID: 23509897 DOI: 10.1111/Liv.12150]
  - 27 **Aronson ID**, Bennett A, Marsch LA, Bania TC. Mobile Technology to Increase HIV/HCV Testing and Overdose Prevention/Response among People Who Inject Drugs. *Front Public Health* 2017; **5**: 217 [PMID: 28879174 DOI: 10.3389/fpubh.2017.00217]
  - 28 **Goldsworthy MA**, Fateen W, Thygesen H, Aldersley MA, Rowe IA, Jones RL. Patient understanding of liver cirrhosis and

- improvement using multimedia education. *Frontline Gastroenterol* 2017; **8**: 214-219 [PMID: 28706622 DOI: 10.1136/flgastro-2016-100761]
- 29 **Hochstatter KR**, Gustafson DH Sr, Landucci G, Pe-Romashko K, Cody O, Maus A, Shah DV, Westergaard RP. Effect of an mHealth Intervention on Hepatitis C Testing Uptake Among People With Opioid Use Disorder: Randomized Controlled Trial. *JMIR Mhealth Uhealth* 2021; **9**: e23080 [PMID: 33616545 DOI: 10.2196/23080]
- 30 **Ochalek TA**, Heil SH, Higgins ST, Badger GJ, Sigmon SC. A novel mHealth application for improving HIV and Hepatitis C knowledge in individuals with opioid use disorder: A pilot study. *Drug Alcohol Depend* 2018; **190**: 224-228 [PMID: 30056321 DOI: 10.1016/j.drugalcdep.2018.05.032]
- 31 **Ooms J**, Hoeks J, Jansen C. "Hey, that could be me": The role of similarity in narrative persuasion. *PLoS One* 2019; **14**: e0215359 [PMID: 30998694 DOI: 10.1371/journal.pone.0215359]
- 32 **Shen, F**, Sheer VC, Li R. Impact of narratives on persuasion in health communication: a meta-analysis. *J Advert* 2015; **44**: 105 [DOI: 10.1080/00913367.2015.1018467]
- 33 **New York State Office of Addiction Services and Supports**. Person-Centered Care Guidance for OASAS Certified Programs Albany, NY: New York State Office of Addiction Services and Supports 2018. [cited 2021 September 9]. Available from: <https://oasas.ny.gov/system/files/documents/2020/01/oasasperson-centeredcareguidance.pdf>
- 34 **International Harm Reduction Association**. What is Harm Reduction? A position statement from the International Harm Reduction Association London, UK: International Harm Reduction Association, 2009. [cited 2021 September 9]. Available from: [https://www.hri.global/files/2010/05/31/IHRA\\_HRStatement.pdf](https://www.hri.global/files/2010/05/31/IHRA_HRStatement.pdf)
- 35 **Abu Abed M**, Himmel W, Vormfelde S, Koschack J. Video-assisted patient education to modify behavior: a systematic review. *Patient Educ Couns* 2014; **97**: 16-22 [PMID: 25043785 DOI: 10.1016/j.pec.2014.06.015]
- 36 **Green MC**, Clark JL. Transportation into narrative worlds: implications for entertainment media influences on tobacco use. *Addiction* 2013; **108**: 477-484 [PMID: 22994374 DOI: 10.1111/j.1360-0443.2012.04088.x]
- 37 **The R Foundation**. A language and environment for statistical computing: R Foundation for Statistical Computing. [cited 2020 December 29]. Available from: <https://www.R-project.org/>
- 38 **WILCOXIN F**. Probability tables for individual comparisons by ranking methods. *Biometrics* 1947; **3**: 119-122 [PMID: 18903631 DOI: 10.2307/3001968]
- 39 **Mann, HB**, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. *Ann Math Statist* 1947; **18**: 50-60 [DOI: 10.1214/aoms/1177730491]
- 40 **Munoz-Plaza CE**, Strauss S, Astone-Twerell J, Jarlais DD, Gwadz M, Hagan H, Osborne A, Rosenblum A. Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. *Int J Drug Policy* 2008; **19**: 71-78 [PMID: 18312822 DOI: 10.1016/j.drugpo.2007.02.003]
- 41 **Talal AH**, McLeod A, Andrews P, Nieves-McGrath H, Chen Y, Reynolds A, Sylvester C, Dickerson SS, Markatou M, Brown LS. Patient Reaction to Telemedicine for Clinical Management of Hepatitis C Virus Integrated into an Opioid Treatment Program. *Telemed J E Health* 2019; **25**: 791-801 [PMID: 30325701 DOI: 10.1089/tmj.2018.0161]
- 42 **Gulati R**, Nawaz M, Pysopoulos NT. Health literacy and liver disease. *Clin Liver Dis (Hoboken)* 2018; **11**: 48-51 [PMID: 30992787 DOI: 10.1002/clid.690]
- 43 **Hochstatter KR**, Gustafson DH Sr, Landucci G, Pe-Romashko K, Maus A, Shah DV, Taylor QA, Gill EK, Miller R, Krechel S, Westergaard RP. A Mobile Health Intervention to Improve Hepatitis C Outcomes Among People With Opioid Use Disorder: Protocol for a Randomized Controlled Trial. *JMIR Res Protoc* 2019; **8**: e12620 [PMID: 31373273 DOI: 10.2196/12620]
- 44 **Sheridan SL**, Halpern DJ, Viera AJ, Berkman ND, Donahue KE, Crotty K. Interventions for individuals with low health literacy: a systematic review. *J Health Commun* 2011; **16** Suppl 3: 30-54 [PMID: 21951242 DOI: 10.1080/10810730.2011.604391]
- 45 **Shah HA**, Abu-Amara M. Education provides significant benefits to patients with hepatitis B virus or hepatitis C virus infection: a systematic review. *Clin Gastroenterol Hepatol* 2013; **11**: 922-933 [PMID: 23639601 DOI: 10.1016/j.cgh.2013.04.024]
- 46 **Green MC**, Brock TC. The role of transportation in the persuasiveness of public narratives. *J Pers Soc Psychol* 2000; **79**: 701-721 [PMID: 11079236 DOI: 10.1037/0022-3514.79.5.701]
- 47 **Hinyard LJ**, Kreuter MW. Using narrative communication as a tool for health behavior change: a conceptual, theoretical, and empirical overview. *Health Educ Behav* 2007; **34**: 777-792 [PMID: 17200094 DOI: 10.1177/1090198106291963]
- 48 **Cohen, J**. Defining identification: a theoretical look at the identification of audiences with media characters. *Mass Commun Soc* 2001; **4**: 245-264 [DOI: 10.1207/S15327825MCS0403\_01]
- 49 **Clark JL**, Green MC, Simons JJP. Narrative warmth and quantitative competence: Message type affects impressions of a speaker. *PLoS One* 2019; **14**: e0226713 [PMID: 31869365 DOI: 10.1371/journal.pone.0226713]
- 50 **Zebregs S**, van den Putte B, Neijens P, de Graaf A. The differential impact of statistical and narrative evidence on beliefs, attitude, and intention: a meta-analysis. *Health Commun* 2015; **30**: 282-289 [PMID: 24836931 DOI: 10.1080/10410236.2013.842528]
- 51 **Ratcliff CL**, Sun Y. Overcoming resistance through narratives: findings from a meta-analytic review. *Hum Commun Res* 2020; **46**: 412-443 [DOI: 10.1093/hcr/hqz017]
- 52 **Perumalswami PV**, Talal AH. Improvements in Quality of Life: A New Indication for Treating Hepatitis C Virus Infection in Persons With Substance Use Disorders. *J Infect Dis* 2018; **217**: 1020-1023 [PMID: 29294033 DOI: 10.1093/infdis/jix682]
- 53 **Cabibbo G**, Petta S, Barbàra M, Missale G, Virdone R, Caturelli E, Piscaglia F, Morisco F, Colecchia A, Farinati F, Giannini E, Trevisani F, Craxi A, Colombo M, Cammà C; ITA. LI.CA study group. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. *Liver Int* 2017; **37**: 1157-1166 [PMID: 28061016 DOI: 10.1111/Liv.13357]
- 54 **Bedogni G**, Miglioli L, Masutti F, Ferri S, Castiglione A, Lenzi M, Crocè LS, Granito A, Tiribelli C, Bellentani S. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. *Am J Gastroenterol* 2008; **103**: 2248-2253 [PMID: 18637095 DOI: 10.1111/j.1572-0241.2008.01948.x]

- 55 **Cunningham EB**, Hajarizadeh B, Amin J, Litwin AH, Gane E, Cooper C, Lacombe K, Hellard M, Read P, Powis J, Dalgard O, Bruneau J, Matthews GV, Feld JJ, Dillon JF, Shaw D, Bruggmann P, Conway B, Fraser C, Marks P, Dore GJ, Grebely J; SIMPLIFY and D3FEAT study groups. Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. *Clin Infect Dis* 2020; **71**: e115-e124 [PMID: [31677262](#) DOI: [10.1093/cid/ciz1089](#)]
- 56 **Hajarizadeh B**, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, Midgard H, Dalgard O, Dillon J, Hickman M, Bruneau J, Dore GJ, Grebely J. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. *J Hepatol* 2020; **72**: 643-657 [PMID: [31785345](#) DOI: [10.1016/j.jhep.2019.11.012](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

